CD19 and neoplasm: Conversely, CD19 chimeric antigen receptor T cell (CAR-T) therapy, which involves T cells engineered to express a chimeric antigen receptor (CAR) that specifically binds to CD19, has shown strong and sustained anti-tumor effects against CD19-positive B-cell malignancies.